Quercetin, luteolin and formononetin can also target disease targets interleukin 4 and interleukin 10 in the anti-inflammatory factor network, thus balancing the role of immune network targets in the treatment of RA. This evidence concerns the gene IL10 and rheumatoid arthritis.